CNBC 快讯 4月22日 11:58 这只制药股相对同业估值低廉——瑞银认为其将迎来反弹 This pharmaceutical stock is cheap relative to peers. UBS thinks it's due for a bounce The investment bank upgraded the pharmaceutical name to buy from neutral. FG 100 读报告 →